The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial

J Pediatr. 2005 Aug;147(2):197-201. doi: 10.1016/j.jpeds.2005.05.015.


Objective: To determine whether oral administration of the probiotic Lactobacillus GG under randomized, double-blinded, placebo-controlled conditions would improve symptoms of irritable bowel syndrome (IBS) in children.

Study design: Fifty children fulfilling the Rome II criteria for IBS were given Lactobacillus GG or placebo for 6 weeks. Response to therapy was recorded and collected on a weekly basis using the Gastrointestinal Symptom Rating Scale (GSRS).

Results: Lactobacillus GG was not superior to placebo in relieving abdominal pain (40.0% response rate in the placebo group vs 44.0% in the Lactobacillus GG group; P=.774). There was no difference in the other gastrointestinal symptoms, except for a lower incidence of perceived abdominal distention (P=.02 favoring Lactobacillus GG).

Conclusions: Lactobacillus GG was not superior to placebo in the treatment of abdominal pain in children with IBS but may help relieve such symptoms as perceived abdominal distention.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Pain / classification
  • Abdominal Pain / etiology
  • Abdominal Pain / therapy*
  • Administration, Oral
  • Adolescent
  • Adult
  • Child
  • Double-Blind Method
  • Female
  • Humans
  • Irritable Bowel Syndrome / classification
  • Irritable Bowel Syndrome / physiopathology
  • Irritable Bowel Syndrome / therapy*
  • Lactobacillus*
  • Male
  • Probiotics / therapeutic use*
  • Severity of Illness Index